WuXi AppTec(WUXAY)
Search documents
医药生物行业资金流出榜:药明康德等12股净流出资金超亿元
Zheng Quan Shi Bao· 2025-08-18 09:18
沪指8月18日上涨0.85%,申万所属行业中,今日上涨的有29个,涨幅居前的行业为通信、综合,涨幅 分别为4.46%、3.43%。医药生物行业今日上涨1.07%。跌幅居前的行业为房地产、石油石化,跌幅分别 为0.46%、0.10%。 资金面上看,两市主力资金全天净流出160.57亿元,今日有8个行业主力资金净流入,电子行业主力资 金净流入规模居首,该行业今日上涨2.48%,全天净流入资金50.40亿元,其次是通信行业,日涨幅为 4.46%,净流入资金为49.04亿元。 主力资金净流出的行业有23个,非银金融行业主力资金净流出规模居首,全天净流出资金70.87亿元, 其次是电力设备行业,净流出资金为50.90亿元,净流出资金较多的还有医药生物、基础化工、房地产 等行业。 医药生物行业今日上涨1.07%,全天主力资金净流出47.06亿元,该行业所属的个股共474只,今日上涨 的有347只,涨停的有7只;下跌的有119只。以资金流向数据进行统计,该行业资金净流入的个股有155 只,其中,净流入资金超亿元的有7只,净流入资金居首的是塞力医疗,今日净流入资金1.52亿元,紧 随其后的是福瑞股份、新天药业,净流入资金分别 ...
医药生物行业资金流出榜:药明康德等12股净流出资金超亿元
Zheng Quan Shi Bao Wang· 2025-08-18 08:59
医药生物行业资金流入榜 | 代码 | 简称 | 今日涨跌幅(%) | 今日换手率(%) | 主力资金流量(万元) | | --- | --- | --- | --- | --- | | 603716 | 塞力医疗 | 5.14 | 21.42 | 15167.42 | | 300049 | 福瑞股份 | 20.00 | 8.88 | 14112.13 | | 002873 | 新天药业 | 10.04 | 21.73 | 12756.46 | | 300003 | 乐普医疗 | 7.50 | 5.21 | 11879.51 | | 600645 | 中源协和 | 5.87 | 7.07 | 10630.01 | | 300204 | 舒泰神 | 3.85 | 5.17 | 10605.35 | | 688189 | 南新制药 | 20.03 | 13.24 | 10160.34 | | 000538 | 云南白药 | 1.57 | 1.14 | 7852.22 | | 600557 | 康缘药业 | 2.15 | 5.69 | 7699.12 | | 002082 | 万邦德 | 10.01 | 3.49 | ...
药明康德(02359.HK)8月18日耗资2999.76万元回购30.79万股A股


Ge Long Hui· 2025-08-18 08:35
格隆汇8月18日丨药明康德(02359.HK)发布公告,2025年8月18日耗资2999.76万元人民币回购30.79万股 A股,回购价格每股96.65-99.12元。 ...
药明康德8月18日斥资2999.76万元回购A股30.79万股


Zhi Tong Cai Jing· 2025-08-18 08:31
药明康德(603259)(02359)发布公告,于2025年8月18日斥资2999.76万元回购A股股份30.79万股,每股 回购价格为96.65-99.12元。 ...
药明康德(02359)8月18日斥资2999.76万元回购A股30.79万股


智通财经网· 2025-08-18 08:30
智通财经APP讯,药明康德(02359)发布公告,于2025年8月18日斥资2999.76万元回购A股股份30.79万 股,每股回购价格为96.65-99.12元。 ...
药明康德(02359) - 翌日披露报表


2025-08-18 08:25
FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別: 股票 狀態: 新提交 公司名稱: 無錫藥明康德新藥開發股份有限公司 第 1 頁 共 12 頁 v 1.3.0 | 1). | 購回股份(或其他證券)但沒有註銷 | 302,500 | 0.01 % | RMB | 66.14 | | --- | --- | --- | --- | --- | --- | | | 茲提述本公司於2025年3月17日刊發的公告,於2025年3月26日刊發的 | | | | | | | 通函,及於2025年4月29日刊發的投票結果公告。 | | | | | | | 於2025年6月26日,本公司實施2025年以集中競價交易方式回購本公司 | | | | | | | A股股份方案("2025年第一次回購"),并回購302,500股A股股份。 | | | | | | | 變動日期 2025年6月26日 | | | | | | 2). | 購回股份(或其他證券)但沒有註銷 | 303,367 | | | | | | | | 0.01 % | RMB | 65.96 | ...
医疗服务行业18日主力净流出14.05亿元,药明康德、创新医疗居前
Sou Hu Cai Jing· 2025-08-18 07:55
Core Insights - The healthcare services sector experienced a rise of 1.26% on August 18, with a net outflow of 1.405 billion yuan in principal funds [1] - Among the constituent stocks, 33 increased in value while 9 decreased [1] Fund Flow Analysis - The top net outflows were recorded for WuXi AppTec at 478 million yuan, Innovent Biologics at 410 million yuan, and Kelun Pharmaceutical at 175 million yuan [1] - Other notable outflows included Sanbo Brain Science at 157 million yuan and Ruizhi Pharmaceutical at 54.73 million yuan [1] Stock Performance - Key stocks with significant performance included: - Kanglong Chemical with a price of 30.94 and an increase of 2.35%, attracting a net inflow of 68.68 million yuan [1] - Baihua Pharmaceutical at 8.78, up 10.03%, with a net inflow of 63.97 million yuan [1] - Aier Eye Hospital at 13.22, up 1.34%, with a net inflow of 784.89 thousand yuan [1] - Huakang Clean at 33.28, up 13.39%, with a net inflow of 3316.13 thousand yuan [1] - Tongce Medical at 46.18, up 2.26%, with a net inflow of 3071.04 thousand yuan [1]
药明康德股价小幅回落 公司斥资2799万元回购股份
Jin Rong Jie· 2025-08-15 16:52
Group 1 - The stock price of WuXi AppTec closed at 97.80 yuan on August 15, 2025, down by 0.89% from the previous trading day [1] - The company operates in the medical services industry and is a global leader in pharmaceutical research and development services, covering drug discovery, development, and manufacturing services [1] - For the first half of 2025, WuXi AppTec reported revenue of 20.799 billion yuan and a net profit attributable to shareholders of 8.561 billion yuan [1] Group 2 - On August 15, WuXi AppTec repurchased 290,000 A-shares, with a total payment amount of 27.99 million yuan [1] - On the same day, the net outflow of main funds was 236 million yuan, while the cumulative net inflow of main funds over the past five trading days was 1.119 billion yuan [1]
中华交易服务香港生物科技指数上涨1.74%,前十大权重包含药明康德等
Jin Rong Jie· 2025-08-15 14:13
Group 1 - The core index, the CESHKB, increased by 1.74% to 9852.81 points with a trading volume of 14.774 billion [1] - The CESHKB index has risen by 20.92% in the past month, 69.27% in the past three months, and 116.13% year-to-date [1] - The index is compiled by China Securities Index Co., Ltd. under the commission of China Securities Trading Service Co., Ltd. and aims to reflect the overall performance of biotechnology companies listed in Hong Kong [1] Group 2 - The top ten weighted stocks in the CESHKB index include: - CanSino Biologics (13.72%) - Innovent Biologics (9.48%) - 3SBio (8.99%) - WuXi Biologics (8.61%) - BeiGene (8.53%) - WuXi AppTec (6.93%) - Kintor Pharmaceutical (4.94%) - Zai Lab (4.28%) - Nuo Therapeutics (4.1%) - Genscript Biotech (3.78%) [1] - The CESHKB index is entirely composed of stocks listed on the Hong Kong Stock Exchange, with 100% allocation [2] - The index's holdings are exclusively in the healthcare sector, with 100% allocation to the pharmaceutical and healthcare industry [2]
药明康德8月15日斥资2799.09万元回购28.55万股A股


Zhi Tong Cai Jing· 2025-08-15 12:38
Core Viewpoint - WuXi AppTec (603259)(02359) announced a share buyback plan, investing 27.99 million RMB to repurchase 285,500 A-shares at a price range of 96.71 to 99.28 RMB per share [1] Group 1 - The company plans to repurchase shares on August 15, 2025 [1] - The total investment for the buyback is 27.99 million RMB [1] - The number of shares to be repurchased is 285,500 [1]